Harnessing DNA Tetrahedral Nanoparticles: A Novel Strategy for Co- delivery of OTUD6B siRNA and DOX Against TNBC Growth and Progression

Author:

Zhang Wenxiang1,Yang Xue1,Gao Ran1,Kong Xiangyi1,Wang Xiangyu1,Liu Qiang1,Qu Zheng1,Zhang Xingsong2,Wang Jing1,Chen Zhengju2,Fang Yi1

Affiliation:

1. National Cancer Center, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

2. Pooling Medical Research Institutes of 100Biotech, Beijing 100006, China

Abstract

Abstract Background Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer lacking specific targeted therapeutic options. The deubiquitinizing enzyme OTUD6B is emerging as a potential player in TNBC progression. Objective The study aimed to ascertain the role of OTUD6B in TNBC progression and to exploit its therapeutic potential using a novel delivery system. Methods OTUD6B expression in TNBC was studied in relation to patient survival outcomes. We explored the potential of OTUD6B siRNA for TNBC treatment and its combined delivery with the chemotherapeutic agent, DOX, using a synthesized DNA tetrahedral nanoparticle (Td). The uptake and efficacy of the siOTUD6B/DOX@Td combination in TNBC cells were then evaluated, alongside an investigation into the underlying molecular mechanisms. Results There was a significant upregulation of OTUD6B in TNBC, inversely correlated with patient survival. The siOTUD6B/DOX@Td composite demonstrated efficient cellular uptake by TNBC cells, leading to the gene silencing of OTUD6B and controlled DOX release. This dual treatment approach enhanced apoptosis rates, increased DOX sensitivity, and inhibited TNBC cell growth, migration, and metastasis. In vivo results further confirmed the inhibition of tumor growth and metastasis without harming primary organs. Mechanistically, OTUD6B influenced TNBC progression through MDM2 stabilization and FOXO3 degradation. Conclusion Our findings highlight the pivotal role of OTUD6B in TNBC progression and underscore the potential of DNA tetrahedral nanoparticles as drug delivery systems. The combined siOTUD6B/DOX@Td strategy offers a promising therapeutic approach for TNBC and demonstrates the broader applicability of DNA nanotechnology in biomedicine.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3